Related Experiment Video

Updated: May 20, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

IL-17A facilitates platelet function through the ERK2 signaling pathway in patients with acute coronary syndrome

Shuang Zhang1, Jing Yuan, Miao Yu

  • 1Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.

Plos One
|July 19, 2012
PubMed

Insights

Interleukin-17A (IL-17A) promotes platelet aggregation and activation in acute coronary syndrome (ACS) patients by activating the ERK2 signaling pathway. This finding suggests IL-17A as a potential target for novel antiplatelet therapies in coronary heart disease (CHD).

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Platelet Biology

Background:

  • Inflammation-mediated platelet aggregation is crucial in coronary heart disease (CHD) development.
  • Th17 cells and IL-17A are linked to plaque destabilization in acute coronary syndrome (ACS).
  • The precise role of IL-17A in platelet-driven atherothrombosis is not fully understood.

Purpose of the Study:

  • To investigate the effect of IL-17A on platelet aggregation and activation in patients with various coronary heart disease (CHD) conditions.
  • To explore the underlying molecular mechanisms, specifically the mitogen-activated protein kinases (MAPKs) pathway, involved in IL-17A-induced platelet responses.
  • To determine if IL-17A could serve as a therapeutic target for antiplatelet strategies in CHD.

Main Methods:

  • Measured plasma IL-17A levels and platelet aggregation in patients with stable angina (SA), unstable angina (UA), acute myocardial infarction (AMI), and chest pain syndrome (CPS).
  • Assessed platelet activation markers (CD62P/PAC-1) and MAPK pathway activation in platelets from ACS patients.
  • Utilized in vitro stimulation of platelets with IL-17A and tested the effect of an ERK2 inhibitor on platelet aggregation and activation.

Main Results:

  • Plasma IL-17A levels and platelet aggregation were significantly higher in ACS patients (UA, AMI) compared to SA and CPS patients.
  • A positive correlation was observed between plasma IL-17A levels and platelet aggregation (R = 0.47, P<0.01).
  • IL-17A stimulation in vitro significantly elevated platelet aggregation, CD62P/PAC-1 expression, and ERK2 pathway phosphorylation in ACS platelets; ERK2 inhibition attenuated these effects.

Conclusions:

  • IL-17A promotes platelet function in ACS patients by activating the ERK2 signaling pathway.
  • This study provides the first evidence of IL-17A's direct role in promoting platelet activity in ACS.
  • IL-17A represents a potential novel target for developing antiplatelet therapies for coronary heart disease (CHD).
Abstract

More Related Videos

Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice05:12

Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice

Published on: August 13, 2015

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers05:43

An In Vitro Assay to Study Platelet Migration Using RGD-Functionalized Avidin-Biotin Tethers

Published on: November 8, 2024

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...